2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 551

Changes in Diverse Disease Activity Measures Are Highly Correlated Following the Initiation of Most Treatment Modalities in the Management of Longstanding Rheumatoid Arthritis
Abstract Number: 353

Changes in Femoral Neck Bone Mineral Density Inverse Correlate with Egfr in Denosumab Treated Osteoporosis Patients? a Hospital-Based Analysis
Abstract Number: 2676

Changes in Salivary Gland Echostructure in Patients with Primary SjöGren’s Syndrome over the Time: A Four-Year Longitudinal Study
Abstract Number: 526

Changes in the Functional Status of the Rheumatoid Arthritis (RA) Population over the Biologic Era
Abstract Number: 2850

Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis
Abstract Number: 542

Changes on Body Composition in Women with Long-Standing Established Rheumatoid Arthritis: Differences By Level of Disease Activity
Abstract Number: 3086

Changing Patterns over Time in Opiate Use in U.S. Rheumatoid Arthritis Patients
Abstract Number: 1918

Characterising the Specificity, Function and Behavior of CD4+ T Cells Initiating Inflammation in a Murine Model of Rheumatoid Arthritis
Abstract Number: 2753

Characteristic and Outcomes of Psoriatic Arthritis Patients with Hyperuricemia, Whether We Should Treat or Not?
Abstract Number: 1202

Characteristic Compositional and Functional Alteration of Gut Microbiota in Patients with Behcet’s Disease
Abstract Number: 1673

Characteristic Phenotypes of Peripheral T Cells and Efficacy of Biological Dmards in Patients with Psoriatic Arthritis
Abstract Number: 2971

Characteristics and Management of IgA Vasculitis (Henoch-Schönlein purpura) in Adults: Data from the 260 Patients Included in the Igavas Survey
Abstract Number: 2749

Characteristics of Ankylosing Spondylitis Patients with Primary and Secondary Lack of Efficacy to TNF-Inhibitor Treatments
Abstract Number: 554

Characteristics of Functional Impairment in Patients with Long-Standing Rheumatoid Arthritis Based on Range of Motion of Joints: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function
Abstract Number: 1314

Characteristics of the Musculoskeletal Symptoms Observed Among Survivors of Ebola Virus Disease (EVD) in the Postebogui Cohort in Guinea

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].